Impact of biomarkers on non-small cell lung cancer treatment.

Targeted oncology

Volumn 5, Issue 1, 2010, Pages 5-17

  Toschi, Luca ^a   Cappuzzo, Federico ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA III TUBULIN PROTEIN, HUMAN; BETA III-TUBULIN PROTEIN, HUMAN; CISPLATIN; DEOXYCYTIDINE; DNA BINDING PROTEIN; DRUG DERIVATIVE; EGFR PROTEIN, HUMAN; ENDONUCLEASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERCC1 PROTEIN, HUMAN; GEMCITABINE; PHARMACOLOGICAL BIOMARKER; RRM1 PROTEIN, HUMAN; TAXOID; TUBULIN; TUMOR SUPPRESSOR PROTEIN;

DRUG ANTAGONISM; DRUG RESISTANCE; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; PROGNOSIS; REVIEW;

ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; HUMANS; LUNG NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TAXOIDS; TUBULIN; TUMOR SUPPRESSOR PROTEINS;

EID: 77956900542     PISSN: None     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-010-0132-y     Document Type: Review

References (138)